Skip to content
Biodatica
Start free

LSU HEALTH SCIENCES CENTER

NEW ORLEANS, LA

Oncologygene editingGrant-only
Compare Sign in to watch

What changed

NIH R01 · $0.7M · Identification and inhibition of the novel downstream effectors of mutant Ras for mutant Ras-driven cancer targeting

5w agoNew grantJun 10, 2026Source filing (opens the source filing in a new tab)

Momentum

73no change

Momentum 73 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

9,234 pre-ticker oncology companies at Grant-only

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    R01 · $693k · non-dilutive

    Jun 9, 2026

    DUKE UNIVERSITY · PI LIN, HUI-KUAN · NCI · award ends May 31, 2031 · Identification and inhibition of the novel downstream effectors of mutant Ras for mutant Ras-driven cancer targeting

    NIH RePORTER · NIH RePORTER 11363259 (opens the source filing in a new tab)

  2. Grant

    R21 · $414k · non-dilutive

    May 1, 2026

    UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIN, HUI · NCI · award ends Apr 30, 2028 · Multi-Modality Modeling of Glioblastoma Progression: Integrating DTI and Prognostic Biomarkers for Personalized Radiation Therapy Targeting

    NIH RePORTER · NIH RePORTER 11371823 (opens the source filing in a new tab)

  3. Trial

    NA registered

    Aug 12, 2025

    Visual Acuity, Accommodation, Dry Eye · ACTIVE_NOT_RECRUITING · sponsor: China Medical University Hospital · Evaluation of the Protective Effects of Cordyceps Cicadae on Visual Function and Anti-Fatigue Performance in Esports Athletes

    ClinicalTrials.gov · NCT07135193 (opens the source filing in a new tab)

  4. Grant

    R01 · $643k · non-dilutive

    May 31, 2023

    UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LI, HONG-YU · NCI · award ends Apr 30, 2028 · Drug Development of Skp2 PROTACs in Cancer

    NIH RePORTER · NIH RePORTER 11319788 (opens the source filing in a new tab)

  5. Grant

    R01 · $507k · non-dilutive

    Feb 9, 2023

    DUKE UNIVERSITY · PI LIN, HUI-KUAN · NCI · award ends Jan 31, 2028 · Identification of a novel targetable cancer stem cell regulator promoting cancer progression and metastasis in non-small cell lung cancer

    NIH RePORTER · NIH RePORTER 11258495 (opens the source filing in a new tab)

  6. Grant

    P20 · $112k · non-dilutive

    Aug 15, 2017

    LSU HEALTH SCIENCES CENTER · PI LIN, HUI-YI · NIGMS · award ends Jun 30, 2027 · Biostatistics and Bioinformatics Core

    NIH RePORTER · NIH RePORTER 11191612 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources